Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer.

Hawkins O, Verma B, Lightfoot S, Jain R, Rawat A, McNair S, Caseltine S, Mojsilovic A, Gupta P, Neethling F, Almanza O, Dooley W, Hildebrand W, Weidanz J.

J Immunol. 2011 Jun 1;186(11):6607-16. doi: 10.4049/jimmunol.1003995. Epub 2011 Apr 22.

2.

Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.

Patterson AM, Kaabinejadian S, McMurtrey CP, Bardet W, Jackson KW, Zuna RE, Husain S, Adams GP, MacDonald G, Dillon RL, Ames H, Buchli R, Hawkins OE, Weidanz JA, Hildebrand WH.

Mol Cancer Ther. 2016 Feb;15(2):313-22. doi: 10.1158/1535-7163.MCT-15-0658. Epub 2015 Dec 30.

3.

Identification of breast cancer peptide epitopes presented by HLA-A*0201.

Hawkins OE, Vangundy RS, Eckerd AM, Bardet W, Buchli R, Weidanz JA, Hildebrand WH.

J Proteome Res. 2008 Apr;7(4):1445-57. doi: 10.1021/pr700761w. Epub 2008 Mar 18.

PMID:
18345606
4.

TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.

Verma B, Neethling FA, Caseltine S, Fabrizio G, Largo S, Duty JA, Tabaczewski P, Weidanz JA.

J Immunol. 2010 Feb 15;184(4):2156-65. doi: 10.4049/jimmunol.0902414. Epub 2010 Jan 11.

5.

Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.

Wittman VP, Woodburn D, Nguyen T, Neethling FA, Wright S, Weidanz JA.

J Immunol. 2006 Sep 15;177(6):4187-95.

6.

Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer.

Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, Zhang Y, Wang S.

Cancer Lett. 2008 Mar 18;261(2):147-57. doi: 10.1016/j.canlet.2007.11.028. Epub 2008 Jan 2.

PMID:
18171602
7.

Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.

Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B, Bernhagen J.

Oncogene. 2007 Aug 2;26(35):5046-59. Epub 2007 Feb 19.

PMID:
17310986
8.

Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer.

Verjans E, Noetzel E, Bektas N, Schütz AK, Lue H, Lennartz B, Hartmann A, Dahl E, Bernhagen J.

BMC Cancer. 2009 Jul 14;9:230. doi: 10.1186/1471-2407-9-230.

9.

Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient.

Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S.

Hum Immunol. 1999 Dec;60(12):1195-206.

PMID:
10626733
10.

Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.

Wang X, Yuan S, Wang J, Lin P, Liu G, Lu Y, Zhang J, Wang W, Wei Y.

Toxicol Appl Pharmacol. 2006 Sep 1;215(2):168-78. Epub 2006 Mar 23.

PMID:
16563451
11.

CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S.

J Natl Cancer Inst. 2010 Oct 6;102(19):1496-512. doi: 10.1093/jnci/djq343. Epub 2010 Sep 17.

12.

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.

Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN.

J Immunol. 2008 Jul 1;181(1):146-54.

13.

TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms.

Verma B, Jain R, Caseltine S, Rennels A, Bhattacharya R, Markiewski MM, Rawat A, Neethling F, Bickel U, Weidanz JA.

J Immunol. 2011 Mar 1;186(5):3265-76. doi: 10.4049/jimmunol.1002376. Epub 2011 Jan 31.

14.

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.

Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM.

Clin Cancer Res. 2010 Apr 1;16(7):2147-56. doi: 10.1158/1078-0432.CCR-09-1611. Epub 2010 Mar 9.

15.
16.
17.

Characterization, epitope identification and mechanisms of the anti-septic capacity of monoclonal antibodies against macrophage migration inhibitory factor.

Zhang Y, Zeng X, Chen S, Zhang Z, Li P, Yi W, Huang H, Yao J, Li S, Hu C.

Int Immunopharmacol. 2011 Sep;11(9):1333-40. doi: 10.1016/j.intimp.2011.04.017. Epub 2011 May 13.

PMID:
21571101
18.

Macrophage migration inhibitory factor is a determinant of hypoxia-induced apoptosis in colon cancer cell lines.

Yao K, Shida S, Selvakumaran M, Zimmerman R, Simon E, Schick J, Haas NB, Balke M, Ross H, Johnson SW, O'Dwyer PJ.

Clin Cancer Res. 2005 Oct 15;11(20):7264-72.

19.

Molecular interaction and enzymatic activity of macrophage migration inhibitory factor with immunorelevant peptides.

Potolicchio I, Santambrogio L, Strominger JL.

J Biol Chem. 2003 Aug 15;278(33):30889-95. Epub 2003 May 9.

Supplemental Content

Support Center